Riluzole in patients with hereditary cerebellar ataxia: A randomised, double-blind, placebo-controlled trial

The Lancet Neurology

Volumn 14, Issue 10, 2015, Pages 985-991

  Romano, Silvia ^a   Coarelli, Giulia ^a   Marcotulli, Christian ^b   Leonardi, Luca ^b   Piccolo, Francesca ^b   Spadaro, Maria ^c   Frontali, Marina ^c   Ferraldeschi, Michela ^a   Vulpiani, Maria Chiara ^a   Ponzelli, Federica ^a   Salvetti, Marco ^a   Orzi, Francesco ^a   Petrucci, Antonio ^d   Vanacore, Nicola ^e   Casali, Carlo ^b   Ristori, Giovanni ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c INSTITUTE OF TRANSLATIONAL PHARMACOLOGY   (Italy)

^d San Camillo Forlanini Foundation   (Italy)

^e ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LIVER ENZYME; PLACEBO; RILUZOLE; AMINO ACID RECEPTOR BLOCKING AGENT;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL ASSESSMENT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FRIEDREICH ATAXIA; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MULTICENTER STUDY; NEUROLOGIST; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHORT FORM 36; SIDE EFFECT; SPINOCEREBELLAR DEGENERATION; UNSPECIFIED SIDE EFFECT; CLINICAL TRIAL; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SPINOCEREBELLAR ATAXIAS; TREATMENT OUTCOME;

ADULT; DOUBLE-BLIND METHOD; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; FRIEDREICH ATAXIA; HUMANS; MALE; MIDDLE AGED; RILUZOLE; SEVERITY OF ILLNESS INDEX; SPINOCEREBELLAR ATAXIAS; TREATMENT OUTCOME;

EID: 84942504487     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(15)00201-X     Document Type: Article

References (30)

1. López-Bastida J, Perestelo-Pérez L, Montón-Alvarez F, Serrano-Aguilar P Social economic costs and health-related quality of life in patients with degenerative cerebellar ataxia in Spain. Mov Disord 2008, 23:212-217.
2. Libri V, Yandim C, Athanasopuolos S, et al. Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich's ataxia: an exploratory, open-label, dose-escalation study. Lancet 2014, 384:504-513.
3. Soragni E, Miao W, Iudicello M, et al. Epigenetic therapy for Friedreich ataxia. Ann Neurol 2014, 76:489-508.
4. Pandolfo M, Arpa J, Delatycki MB, et al. Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial. Ann Neurol 2014, 76:509-521.
5. Arpa J, Sanz-Gallego I, Rodriguez-de-Rivera FJ, et al. triple therapy with deferiprone, idebenone, and riboflavin in Friedreich's ataxia-open-label trial. Acta Neurol Scand 2014, 129:32-40.
6. Zesiewicz TA, Greenstein PE, Sullivan KL, et al. A randomized trial of varenicline (CHANTIX) for treatment of spinocerebellar ataxia type 3. Neurology 2012, 78:545-550.
7. Saute JA, de Castilhos RM, Monte TL, et al. A randomized phase 2 clinical trial of lithium carbonate in Machado-Joseph disease. Mov Disord 2014, 29:568-573.
8. 2+ influx reduction rescues ataxia in CSA28 model. J Clin Invest 2015, 125:263-274.
9. Lagedrost SJ, Sutton MS, Cohen MS, et al. Idebenone in Friedreich ataxia cardiomyopathy-results from a 6-month phase III study (IONIA). Am Heart J 2011, 161:639-645.
10. Mariotti C, Fancellu R, Caldarazzo S, et al. Erythropoietin in Friedreich's ataxia: no effect on frataxin in a randomized controlled trial. Mov Disord 2012, 27:446-449.
11. Ristori G, Romano S, Visconti A, et al. Riluzole in cerebellar ataxia: a randomized, double-blind, placebo-controlled pilot trial. Neurology 2010, 74:839-845.
12. Cao YJ, Dreixler JC, Couey JJ, Houamed KM Modulation of recombinant and native neuronal SK channels by the neuroprotective drug riluzole. Eur J Pharmacol 2002, 449:47-54.
13. Shakkottai VG, Chou CH, Oddo S, et al. Enhanced neuronal excitability in the absence of neurodegeneration induces cerebellar ataxia. J Clin Invest 2004, 113:582-590.
14. Shakkottai VG, do Carmo Costa M, Dell'Orco JM, Sankaranarayanan A, Wulff H, Paulson HL Early changes in cerebellar physiology accompany motor dysfunction in the polyglutamine disease spinocerebellar ataxia type 3. J Neurosci 2011, 31:13002-13014.
15. Gao Z, Todorov B, Barrett CF, et al. Cerebellar ataxia by enhanced Ca(V)2.1 currents is alleviated by Ca2+-dependent K+-channel activators in Cacna1a(S218L) mutant mice. J Neurosci 2012, 32:15533-15546.
16. Kasumu AW, Hougaard C, Rode F, et al. Selective positive modulator of calcium-activated potassium channels exerts beneficial effects in a mouse model of spinocerebellar ataxia type 2. Chem Biol 2012, 26:1340-1353.
17. Lam J, Coleman N, Garing A, Wulff H The therapeutic potential of small-conductance Kca2 channels in neurodegenerative and psychiatric diseases. Expert Opin Ther Targets 2013, 17:1203-1220.
18. Schmitz-Hübsch T, du Montcel ST, Baliko L, et al. Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology 2006, 66:1717-1720.
19. Apolone G, Mosconi P, Ware JE SF-36 Questionario sullo stato di salute. Manuale d'uso e guida all'interpretazione dei risultati 1997, Guerini & Associati Editore, Milan.
20. Beck AT, Steer RA Manual for the Beck Depression Inventory 1993, The Psychological Corporation, San Antonio, TX.
21. Schmitz-Hubsh T, Fimmers R, Rakowicz M, et al. Responsiveness of different rating instruments in spinocerebellar ataxia patients. Neurology 2010, 74:678-684.
22. Marelli C, Figoni J, Charles P, et al. Annual change in Friedreich's ataxia evaluated by the scale for the assessment and rating of ataxia (SARA) is independent of disease severity. Mov Disord 2012, 27:135-138.
23. Kim BR, Lim JH, Lee SA, et al. Usefulness of the Scale for the Assessment and Rating of Ataxia (SARA) in ataxic stroke patients. Ann Rehabil Med 2011, 35:772-780.
24. Burk K, Malzig U, Wolf S, et al. Comparison of three clinical rating scales in Friedreich ataxia (FRDA). Mov Disord 2009, 24:1779-1784.
25. Bensimon G, Doble A The tolerability of riluzole in the treatment of patients with amyotrophic lateral sclerosis. Expert Opin Drug Saf 2004, 3:525-534.
26. Jacobi H, Bauer P, Giunti P, et al. The natural history of spinocebellar ataxia 1, 2, 3 and 6: a 2-year follow-up study. Neurology 2011, 77:1035-1041.
27. Reetz K, Dogan I, Costa AS, et al. Biological and clinical characteristics of the European Friedreich's ataxia consortium for translational studies (EFACTS) cohort: a cross-sectional analysis of baseline data. Lancet Neurol 2015, 14:174-182.
28. Pittenger C, Coric V, Banasr M, Bloch M, Krystal JH, Sanacora G Riluzole in the treatment of mood and anxiety disorders. CNS Drugs 2008, 22:761-786.
29. Cifra A, Mazzone GL, Nistri A Rilzole: what it does to spinal and brainstem neurons and how it does it. Neuroscientist 2012, 19:137-144.
30. Bittner S, Ruck T, Schuhmann MK, et al. Endothelial TWIK-related potassium channel-1 (TREK1) regulates immune-cell trafficking into the CNS. Nat Med 2013, 19:1161-1165.